Latest Capital Raises News

Estrella Resources has entered a $2 million underwriting agreement to support the exercise of its listed options, ensuring capital inflow ahead of the December expiry.

Pursuit Minerals has delivered a compelling Pre-Feasibility Study for its Rio Grande Sur lithium project in Argentina, confirming strong economics and a maiden Ore Reserve. The company also secured a A$7 million capital raise to advance development.

Arcadia Minerals Limited has had its trading suspension lifted following a significant announcement about a proposed capital raising and an earn-in agreement on the Swanson Tantalum Mine.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

First Au Limited has successfully raised $5.6 million in a placement to fund exploration at its Gimlet Gold Project and expand its Western Australian gold strategy.

FireFly Metals has agreed to sell its Ontario gold assets to Bellavista Resources for up to A$86.1 million in shares and performance rights, unlocking value for shareholders while focusing on its copper-gold growth strategy.

FireFly Metals has agreed to sell its Ontario gold assets, including a 70% stake in the Pickle Crow Project, to Bellavista Resources for up to A$86.1 million in scrip. FireFly shareholders will receive Bellavista shares, maintaining exposure to the assets while FireFly focuses on its copper-gold ambitions.

Cyprium Metals has completed the first tranche of a A$36 million placement, positioning itself to fast-track exploration and production growth at its Nifty Copper Complex in Western Australia.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Adavale Resources has raised $5.15 million in a strongly supported placement to fund an expanded drilling program at its London Victoria Gold Mine and advance regional exploration efforts.

Genetic Signatures has appointed Maria Halasz as its new CEO, bringing over two decades of leadership in life sciences and capital markets to steer the company’s global expansion.